Almirall News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Trading-Depot	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Trading-Depot

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

11.11.24	Almirall’s Nine-Month 2024 Results: Almirall Reports Strong Performance at Q3 2024 - Driven by Successful Commercial Execution of the Dermatology Portfolio, Fuelled by Biologics Growth (Businesswire)
15.10.24	Almirall Announces Completion of Decentralized Regulatory Approval Procedure for Efinaconazole in Europe (Businesswire)
25.09.24	New Data Show Almirall´s EBGLYSS® (Lebrikizumab) Provided Sustained Disease Control for up to Three Years in More Than 80% of Adults and Adolescents With Moderate-to-severe Atopic Dermatitis (Businesswire)
23.09.24	Almirall to Present New Data on Biologics for Psoriasis and Atopic Dermatitis and Celebrates 80 Years of Innovation at the EADV Congress (Businesswire)
10.07.24	NICE Recommends Ebglyss (lebrikizumab) for Use in Moderate to Severe Atopic Dermatitis in the NHS England in Eligible Adolescents and Adults (Businesswire)
02.07.24	Almirall Launches Act4Impact – its Updated Sustainability Strategy Setting Ambitious Targets for 2030 (Businesswire)
28.06.24	Almirall’s Ilumetri® (tildrakizumab) Restores and Maintains Wellbeing of Patients With Moderate-to-severe Plaque Psoriasis to the Levels of the General Population for up to 1 Year1 (Businesswire)
13.05.24	Almirall Delivers Strong Start of 2024 – Q1 Net Sales Growth of 6.6% Overall and 18% in the European Dermatology Business, Driven by Biologics and Solid Performance of Broad Product Portfolio (Businesswire)
13.03.24	Almirall and Eloxx Pharmaceuticals Enter into Exclusive Agreement to License ZKN-013 for Rare Dermatological Diseases (Businesswire)
19.02.24	Almirall Licenses an Anti-IL-21 Monoclonal Antibody From Novo Nordisk to Develop It as a First-in-Class Agent in Dermatology (Businesswire)
19.02.24	Almirall continues its progress to leadership in Medical Dermatology driven by strong growth in the European Dermatology business (Businesswire)
21.12.23	Almirall Initiates First Phase I Clinical Study of ALM223, an Interleukin 2 Mutant Fusion Protein for Autoimmune Diseases (Businesswire)
12.12.23	Almirall and etherna Enter Into a Multi-Target Alliance to Develop mRNA-based Therapies in Medical Dermatology (Businesswire)
17.11.23	Almirall Receives European Commission Approval of EBGLYSS® (lebrikizumab) for Moderate-to-Severe Atopic Dermatitis (Businesswire)
14.11.23	Almirall and Absci announce AI drug discovery partnership to rapidly develop novel treatments for dermatological diseases (Businesswire)
09.11.23	Almirall’s Nine-month 2023 Results: (Businesswire)
20.10.23	Almirall: Nearly 80% of patients with moderate-to-severe atopic dermatitis maintained clear or almost-clear skin with lebrikizumab monthly maintenance dosing at two years (Businesswire)
13.10.23	Almirall's Lebrikizumab Improves Signs and Symptoms of Moderate-to-Severe Atopic Dermatitis (AD) in Patients Inadequately Controlled With or Ineligible for Cyclosporine1 (Businesswire)
11.10.23	Almirall's Ilumetri® (tildrakizumab) Significantly Improves Wellbeing for Patients1 and Their Relatives2 in Moderate-to-Severe Plaque Psoriasis (Businesswire)
18.09.23	EBGLYSS® (Lebrikizumab) erhält positive CHMP-Stellungnahme für mittelschwere bis schwere atopische Dermatitis (Businesswire)
15.09.23	EBGLYSS® (lebrikizumab) Receives Positive CHMP Opinion for Moderate-to-severe Atopic Dermatitis (Businesswire)
24.07.23	Almirall’s H1 2023 Results: Almirall Achieves Net Sales Growth of 7% to €466.1MM, Driven by Strong Growth in European Dermatology Business (Businesswire)
07.07.23	Almirall: Ilumetri® (tildrakizumab) significantly improved the wellbeing of patients with moderate-to-severe plaque psoriasis (Businesswire)
20.06.23	Almirall launches Nina, the first series to highlight the major impact of psoriasis on patient’s wellbeing (Businesswire)
13.06.23	Almirall announces the pricing and closing of its €200mm non pre-emptive share capital increase (Businesswire)
12.06.23	Almirall Announces the Launch of a €200mm Non Pre-Emptive Share Capital Increase (Businesswire)
08.05.23	Almirall’s First Quarter 2023 Results (Businesswire)
01.05.23	Almirall: Up to 73% of Atopic Dermatitis Patients Taking Lebrikizumab Had Improved or Cleared Skin on Face or Hands in New Analysis (Businesswire)
12.04.23	Almirall, The First to Assess Wellbeing in a Dermatology Clinical Study (Businesswire)
20.02.23	Almirall’s Full-Year 2022 Results (Businesswire)
04.01.23	Almirall to Participate in the 41st Annual J.P. Morgan Healthcare Conference (Businesswire)
28.11.22	Almirall joins FACILITATE, a patient-driven Innovative Medicines Initiative (IMI) project to enable the use of clinical trial data by study participants (Businesswire)
10.11.22	Almirall’s Nine-month 2022 Results (Businesswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Alcon	60.32	2.31 %	K V
Geberit	601.80	1.83 %	K V
Givaudan	3’262.00	0.25 %	K V
Roche Hldg G	260.10	0.23 %	K V
Novartis	99.52	0.02 %	K V
ABB	58.30	-1.85 %	K V
Part Grp Hldg	949.60	-2.20 %	K V
Logitech Intl	96.42	-2.25 %	K V
Kuehne+Nagel Int	150.00	-2.50 %	K V
CieFinRichemont	157.40	-2.72 %	K V

Almirall Aktie VALOR 3180354 / ISIN ES0157097017

Nachrichten zu Almirall

Aktien Top/Flop

Meistgelesene Nachrichten